Sialic acid-binding Ig-like lectin 10 (SIGLEC10) has emerged as a premier innate immune checkpoint in oncology. Serving as the primary receptor for CD24 (the "don't eat me" signal), the CD24-SIGLEC10 axis shields tumor cells from macrophage-mediated phagocytosis. Targeting SIGLEC10 presents a highly selective therapeutic window to restore anti-tumor innate immunity across solid tumors and hematological malignancies.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SIGLEC10 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SIGLEC10 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View SIGLEC10 Products |
| Gene Delivery | SIGLEC10 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cell-based binding assays. |
View SIGLEC10 Products |
| Benchmark Ab | Anti-SIGLEC10 Recombinant Antibody Recombinant positive control for blocking and flow cytometry assays. |
View SIGLEC10 Products |
| Validator | SIGLEC10 siRNA Set For target knockdown verification in primary macrophages. |
View SIGLEC10 Products |
| Related Target A | CD24 The primary ligand for SIGLEC10; essential for establishing CD24-SIGLEC10 interaction blocking assays. |
View CD24 Products |
| Related Target B | SIGLEC9 Closely related Siglec family member; required for off-target and selectivity counter-screening. |
View SIGLEC9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Cynomolgus, and Mouse ortholog proteins available with >95% purity by SDS-PAGE. |
| Subfamily counter-screening (Siglec-3/5/9) | Homolog panel proteins strictly verified by mass spectrometry to guarantee sequence identity. |
| Lack of Controls | Clinical-grade benchmark antibodies included in the catalog for assay standardization. |
| False Positives | Sequence-validated siRNA pools included for target-specific knockdown validation. |
Live SIGLEC10 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SIGLEC10 therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific/multispecific platforms and antibody-drug conjugates (ADCs). As first-generation therapies targeting the CD24-SIGLEC10 axis reach clinical evaluation, the next wave of R&D is targeting synergistic combinations with T-cell checkpoints (PD-1/PD-L1) and optimizing the selectivity of SIGLEC10 blockers to avoid off-target binding to highly homologous Siglec family members on immune cells.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Oncolytic/Biotech Startups | Ovarian Cancer, Breast Cancer, Colorectal Cancer | Blocking Assay (Need high-purity CD24 and SIGLEC10 ECD-Fc) |
| Bispecific Antibodies | Immuno-oncology Innovators | Solid Tumors with high CD24 expression | Dual-binding validation (Need biologically active, native-glycosylated target proteins) |
| Cell Therapies (CAR-M / CAR-NK) | Academic & Clinical Pioneers | Refractory Solid Tumors | Stable cell line construction (Need high-titer Lentivirus for SIGLEC10 expression) |